Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.59 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Integra Lifesciences Holdings's Beneish M-Score or its related term are showing as below:
STU:IL3'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.09 Med: -2.58 Max: -2.05
Current: -2.59
During the past 13 years, the highest Beneish M-Score of Integra Lifesciences Holdings was -2.05. The lowest was -3.09. And the median was -2.58.
Integra Lifesciences Holdings Beneish M-Score Related Terms
Integra Lifesciences Holdings Beneish M-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:IL3 vs ATEC, AHCO, INSP: Beneish M-Score Comparison
For the Medical Devices subindustry, Integra Lifesciences Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Integra Lifesciences Holdings for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.0453
+
0.528 * 1.0313
+
0.404 * 0.8655
+
0.892 * 0.937
+
0.115 * 1.0096
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.9402
+
4.679 * -0.015999
-
0.327 * 1.1441
=
-2.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(136.863 / (136.863 + 519.273))
/
(131.561 / (131.561 + 505.228))
=
0.208589
/
0.206601
=
1.0096
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-429.744 - -441.387
-
61.156)
/
3094.733
=
-0.015999
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Integra Lifesciences Holdings has a M-score of -2.64 suggests that the company is unlikely to be a manipulator.
Integra Lifesciences Holdings (STU:IL3) has a Beneish M-Score of -2.59 as of Jul. 16, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Integra Lifesciences Holdings and its competitors. According to the industry distribution chart, Integra Lifesciences Holdings ranks #374 out of 763 companies in the Medical Devices & Instruments industry, placing it in the top 49%.
Is Integra Lifesciences Holdings' Beneish M-Score too high?
Integra Lifesciences Holdings' current Beneish M-Score is -2.59. Based on the distribution chart, Integra Lifesciences Holdings ranks #374 out of 763 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Integra Lifesciences Holdings has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' Beneish M-Score compare to ATEC and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #374 out of 763 companies for Beneish M-Score. This puts Integra Lifesciences Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Integra Lifesciences Holdings and its competitors. Integra Lifesciences Holdings's current Beneish M-Score is -2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (STU:IL3) is currently considered Modestly Undervalued. The stock's GF Value™ is €20.79, compared to a current price of €16.40 — trading 21.1% below its estimated fair value. The current Beneish M-Score is -2.59. Integra Lifesciences Holdings' overall GF Score™ is 74/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Integra Lifesciences Holdings (STU:IL3), the current Beneish M-Score is -2.59 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (STU:IL3) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of €16.40 is trading 21.1% below its estimated GF Value™ of €20.79.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for STU:IL3:
Beneish M-Score: -2.59
GF Value™: €20.79 vs. price of €16.40 (21.1% below fair value)
No single metric tells the full story. See the STU:IL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Business Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
74GF Score
Get the complete analysis for STU:IL3
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IL3 has been successfully added to your 
